荣昌生物（09995.HK）今日盘中大涨9.60%，股价延续强劲上涨势头。该公司股价本月内已累计上涨超过三成，引发市场高度关注。
消息面上，荣昌生物近日公布了其自主研发的创新药泰它西普（telitacicept）用于治疗全身型重症肌无力（gMG）的三期临床研究结果。数据显示，泰它西普在治疗24周后，98.1%的患者重症肌无力日常活动评分（MG-ADL）改善≥3分，87%的患者定量重症肌无力评分（QMG）改善≥5分，展现出显著的临床疗效。目前，泰它西普用于治疗全身型重症肌无力的上市申请已于去年10月获CDE受理，并被纳入优先审评，预计将于今年第二季度在中国获批上市。
交银国际分析认为，泰它西普的gMG三期临床数据优于已上市竞品，且公司的商业化推广策略清晰。该机构看好gMG适应症获批后对泰它西普销售放量的长期推动作用。此外，荣昌生物宣布将于4月28日举行董事会会议，审议并批准2025年第一季度未经审计业绩，这可能进一步增强了投资者对公司业绩的期待。随着新药研发进展顺利和潜在的业绩增长，市场对荣昌生物的前景保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.